Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1966 3
1967 9
1968 15
1969 8
1970 21
1971 23
1972 17
1973 37
1974 41
1975 22
1976 23
1977 14
1978 18
1979 19
1980 34
1981 37
1982 23
1983 28
1984 43
1985 47
1986 52
1987 50
1988 101
1989 134
1990 116
1991 159
1992 161
1993 184
1994 189
1995 201
1996 207
1997 186
1998 216
1999 229
2000 198
2001 212
2002 243
2003 217
2004 261
2005 269
2006 279
2007 283
2008 308
2009 332
2010 361
2011 354
2012 370
2013 384
2014 409
2015 388
2016 373
2017 370
2018 388
2019 317
2020 358
2021 284
2022 248
2023 177
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

9,218 results

Results by year

Filters applied: . Clear all
Page 1
Tumor angiogenesis and vascular normalization: alternative therapeutic targets.
Viallard C, Larrivée B. Viallard C, et al. Angiogenesis. 2017 Nov;20(4):409-426. doi: 10.1007/s10456-017-9562-9. Epub 2017 Jun 28. Angiogenesis. 2017. PMID: 28660302 Review.
Tumor blood vessels are a key target for cancer therapeutic management. Tumor cells secrete high levels of pro-angiogenic factors which contribute to the creation of an abnormal vascular network characterized by disorganized, immature and permeable …
Tumor blood vessels are a key target for cancer therapeutic management. Tumor cells secrete high levels of pro-angiogenic fact …
Venous malformations.
Markovic JN, Shortell CK. Markovic JN, et al. J Cardiovasc Surg (Torino). 2021 Oct;62(5):456-466. doi: 10.23736/S0021-9509.21.11911-1. Epub 2021 Jun 9. J Cardiovasc Surg (Torino). 2021. PMID: 34105926 Free article. Review.
The often inexorable growth and expansion of congenital vascular malformations can result in substantial morbidity and, in some cases, premature death of these patients. Despite this, patients suffering from such lesions are often erroneously diagnosed and/or inadeq …
The often inexorable growth and expansion of congenital vascular malformations can result in substantial morbidity and, in som …
Improving immune-vascular crosstalk for cancer immunotherapy.
Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Huang Y, et al. Nat Rev Immunol. 2018 Mar;18(3):195-203. doi: 10.1038/nri.2017.145. Epub 2018 Jan 15. Nat Rev Immunol. 2018. PMID: 29332937 Free PMC article. Review.
The vasculature of tumours is highly abnormal and dysfunctional. Consequently, immune effector cells have an impaired ability to penetrate solid tumours and often exhibit compromised functions. ...However, recent studies have demonstrated that the stimulation of immune cel …
The vasculature of tumours is highly abnormal and dysfunctional. Consequently, immune effector cells have an impaired ability to pene …
Genetic Basis and Therapies for Vascular Anomalies.
Queisser A, Seront E, Boon LM, Vikkula M. Queisser A, et al. Circ Res. 2021 Jun 25;129(1):155-173. doi: 10.1161/CIRCRESAHA.121.318145. Epub 2021 Jun 24. Circ Res. 2021. PMID: 34166070 Review.
Vascular and lymphatic malformations represent a challenge for clinicians. ...The era of theranostics has started for the treatment of vascular anomalies. Registration: URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2015-001703-32....
Vascular and lymphatic malformations represent a challenge for clinicians. ...The era of theranostics has started for the treatment o …
Basic and therapeutic aspects of angiogenesis.
Potente M, Gerhardt H, Carmeliet P. Potente M, et al. Cell. 2011 Sep 16;146(6):873-87. doi: 10.1016/j.cell.2011.08.039. Cell. 2011. PMID: 21925313 Free article. Review.
Blood vessels form extensive networks that nurture all tissues in the body. ...Therapeutic approaches to block vascular supply have reached the clinic, but limited efficacy and resistance pose unresolved challenges. ...
Blood vessels form extensive networks that nurture all tissues in the body. ...Therapeutic approaches to block vascular …
Diabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches.
Madonna R, Balistreri CR, Geng YJ, De Caterina R. Madonna R, et al. Vascul Pharmacol. 2017 Mar;90:1-7. doi: 10.1016/j.vph.2017.01.004. Epub 2017 Jan 28. Vascul Pharmacol. 2017. PMID: 28137665 Free article. Review.
Diabetic microangiopathy, including retinopathy, is characterized by abnormal growth and leakage of small blood vessels, resulting in local edema and functional impairment of the depending tissues. ...We also highlight how new insights into pathogenic mechani …
Diabetic microangiopathy, including retinopathy, is characterized by abnormal growth and leakage of small blood vessels …
Vascular endothelial cell specification in health and disease.
Marziano C, Genet G, Hirschi KK. Marziano C, et al. Angiogenesis. 2021 May;24(2):213-236. doi: 10.1007/s10456-021-09785-7. Epub 2021 Apr 12. Angiogenesis. 2021. PMID: 33844116 Free PMC article. Review.
The blood vasculature carries oxygen, nutrients, circulating cells, and soluble factors to and from every tissue. The lymphatic vasculature maintains interstitial fluid homeostasis, transports hematopoietic cells for immune surveillance, and absorbs fat from the gastrointe …
The blood vasculature carries oxygen, nutrients, circulating cells, and soluble factors to and from every tissue. The lymphatic vascu …
VEGF as a key mediator of angiogenesis in cancer.
Carmeliet P. Carmeliet P. Oncology. 2005;69 Suppl 3:4-10. doi: 10.1159/000088478. Epub 2005 Nov 21. Oncology. 2005. PMID: 16301830 Review.
It is the key mediator of angiogenesis (the formation of new blood vessels), and binds two VEGF receptors (VEGF receptor-1 and VEGF receptor-2), which are expressed on vascular endothelial cells. ...Tumor vasculature formed under the influence of VEGF is stru …
It is the key mediator of angiogenesis (the formation of new blood vessels), and binds two VEGF receptors (VEGF receptor-1 and …
Congenital portosystemic shunts: diagnosis and treatment.
Franchi-Abella S, Gonzales E, Ackermann O, Branchereau S, Pariente D, Guérin F; International Registry of Congenital Portosystemic Shunt members. Franchi-Abella S, et al. Abdom Radiol (NY). 2018 Aug;43(8):2023-2036. doi: 10.1007/s00261-018-1619-8. Abdom Radiol (NY). 2018. PMID: 29730740 Review.
Congenital portosystemic shunts (CPSS) are rare vascular malformations that create an abnormal connection between portal and systemic veins resulting in complete or partial diversion of the portal flow away from the liver to the systemic venous system. ...Int …
Congenital portosystemic shunts (CPSS) are rare vascular malformations that create an abnormal connection between porta …
Normalization of the vasculature for treatment of cancer and other diseases.
Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Goel S, et al. Physiol Rev. 2011 Jul;91(3):1071-121. doi: 10.1152/physrev.00038.2010. Physiol Rev. 2011. PMID: 21742796 Free PMC article. Review.
The imbalance of pro- and anti-angiogenic signaling within tumors creates an abnormal vascular network that is characterized by dilated, tortuous, and hyperpermeable vessels. The physiological consequences of these vascular abnormalities include …
The imbalance of pro- and anti-angiogenic signaling within tumors creates an abnormal vascular network that is characterized b …
9,218 results